1. Show article details.

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Business Wire – 4:30 PM ET 08/18/2022

    Geron Corporation (GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 365,800 shares of Geron (GERN) common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

  2. Show article details.

    Cowen Slashes Price Target On This Stock By Over 78%; Also Check Out Some Other Big PT Changes

    Benzinga – 9:14 AM ET 08/12/2022

    Don't forget to check out our premarket coverage here . Check out this: Illumina, CS Disco And Some Other Big Stocks Moving Lower In Today's Pre-Market Session

  3. Show article details.

    BRIEF-Geron Corporation Reports Second Quarter 2022 Financial Results

    Reuters – 4:22 PM ET 08/11/2022

    Geron Corp (GERN): * ORATION REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS. * Q2 LOSS PER SHARE $0.07. * CURRENT AND PROJECTED FINANCIAL RESOURCES EXPECTED TO SUPPORT PLANNED MILESTONES AND OPERATIONS THROUGH MIDDLE OF 2024. * TOP-LINE RESULTS FROM IMERGE PHASE 3 TRIAL IN LOWER RISK MDS CONTINUE TO BE EXPECTED IN EARLY JANUARY 2023.

  4. Show article details.

    Recap: Geron Q2 Earnings

    Benzinga – 4:21 PM ET 08/11/2022

      Geron reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Geron beat estimated earnings by 22.22%, reporting an EPS of $-0.07 versus an estimate of $-0.09. Revenue was down $34 thousand from the same period last year.

  5. Show article details.

    Geron Corporation Reports Second Quarter 2022 Financial Results

    Business Wire – 4:05 PM ET 08/11/2022

    Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Current and Projected Financial Resources Expected to Support Planned Milestones and Operations Through Middle of 2024 Conference Call Scheduled for 4:30 p.m. ET Today FOSTER CITY, Calif.

  6. Show article details.

    Earnings Scheduled For August 11, 2022

    Benzinga – 5:09 AM ET 08/11/2022

      ** Magic Software is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. ** Dingdong is likely to report earnings for its second quarter. ** Evelo Biosciences is projected to report earnings for its second quarter. ** Affimed is estimated to report quarterly loss at $0.17 per share on revenue of $8.67 million.

  7. Show article details.

    Geron to Announce Second Quarter 2022 Financial Results on August 11, 2022

    Business Wire – 4:30 PM ET 08/04/2022

    Geron Corporation (GERN) today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron (GERN) will host a conference call to discuss the financial results as well as key upcoming expected milestones at 4:30 p.m. ET the same day.

  8. Show article details.

    10 Health Care Stocks With Whale Alerts In Today's Session

    Benzinga – 2:00 PM ET 08/04/2022

    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.

  9. Show article details.

    Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

    Business Wire – 4:30 PM ET 08/03/2022

    Geron Corporation (GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m. ET.

  10. Show article details.

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Business Wire – 7:05 PM ET 07/21/2022

    Geron Corporation (GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 405,800 shares of Geron (GERN) common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

  11. Show article details.

    BRIEF-Geron Corporation Announces Expansion Of Existing Loan Facility

    Reuters – 6:00 PM ET 06/30/2022

    Geron Corp (GERN): * GERON CORPORATION ANNOUNCES EXPANSION OF EXISTING LOAN FACILITY. * Geron Corp (GERN) - AMENDMENT TO EXPAND ITS EXISTING LOAN FACILITY WITH HERCULES CAPITAL AND SILICON VALLEY BANK, FROM UP TO $75 MILLION TO UP TO $125 MILLION. * Geron Corp (GERN) - OF AGGREGATE $125 MILLION LOAN FACILITY, $50 MILLION IS CURRENTLY OUTSTANDING.

  12. Show article details.

    Geron Corporation Announces Expansion of Existing Loan Facility

    Business Wire – 4:15 PM ET 06/30/2022

    Up to $50 Million in Additional Non-Dilutive Capital Potentially Available in 2023 Geron Corporation (GERN), a late-stage clinical biopharmaceutical company, today announced an amendment to expand its existing loan facility with Hercules Capital, Inc. (HTGC) and Silicon Valley Bank, from up to $75 million to up to $125 million.

  13. Show article details.

    Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Business Wire – 4:30 PM ET 06/16/2022

    Geron Corporation (GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 70,000 shares of Geron (GERN) common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.

  14. Show article details.

    Geron Corporation Announces Appointment of Faye Feller, M.D. to Chief Medical Officer and Transition of Aleksandra Rizo, M.D., Ph.D. to Senior Advisor Role

    Business Wire – 4:10 PM ET 06/15/2022

    Geron Corporation (GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Faye Feller, M.D., to Executive Vice President and Chief Medical Officer, effective July 9, 2022.

  15. Show article details.

    Lead Plaintiffs and Class Representatives Julia Junge and Richard Junge Announce Summary Notice of Pendency of Class Action (Nasdaq: GERN)

    PR Newswire – 8:00 AM ET 06/06/2022

    SAN FRANCISCO, June 6, 2022  . UNITED STATES DISTRICT COURTNORTHERN DISTRICT OF CALIFORNIASAN FRANCISCO DIVISION SUMMARY NOTICE OF PENDENCY OF CLASS ACTION To: All persons who purchased GERON CORPORATION (GERN) common stock during the period from March 19, 2018, to September 26, 2018, inclusive, and who were damaged thereby.

  16. Show article details.

    103 Biggest Movers From Yesterday

    Benzinga – 6:22 AM ET 05/11/2022

    103 Biggest Movers From Yesterday

  17. Show article details.

    51 Biggest Movers From Yesterday

    Benzinga – 5:41 AM ET 03/31/2022

  18. Show article details.

    35 Stocks Moving In Wednesday's Mid-Day Session

    Benzinga – 12:24 PM ET 03/30/2022

    35 Stocks Moving In Wednesday's Mid-Day Session

  19. Show article details.

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    Benzinga – 9:17 AM ET 03/30/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  20. Show article details.

    The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict

    Benzinga – 7:46 AM ET 03/30/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours.

Page:

Today's and Upcoming Events

  • Nov
    07

    GERN to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    11

    GERN announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.